Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CovIran-Barkat adolescent phase 1/2 trial versus Sinopharm
IRCT20171122037571N3Phase 2Completed
- Sponsor
- Shifa Pharmed
- Start
- Nov 2021
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of BBIBP-CorV in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Shifa Pharmed. Primary endpoints: Adverse events, Humoral immunity and 3 more. Started Nov 2021; status: completed.
02
Drugs
BBIBP-CorV
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20171122037571N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20171122037571N3.